CLINICA 100 TOP 10: Roche Diagnostics
This article was originally published in Clinica
Roche Diagnostics remains at No 6 in our Clinica 100 and continues to hold on as leader of the IVD sector. While not the most acquisitive buyer, Roche has been a consistent shopper, adding mainly smaller, bolt-on technologies to its molecular diagnostics offering. In 2014, it made six acquisitions, mostly of undisclosed amounts or under $500m. It made the same number of acquisition in 2015, but it dug deeper in its pocket this year and signed a deal worth up to $1.2bn to gain a majority stake in Foundation Medicine, a molecular information and genomic analysis firm. See how Roche Diagnostics performed in the last five years.
You may also be interested in...
Minimally invasive glaucoma surgery specialist Glaukos saw its stock leap 40% in the wake of a worldwide recall by much bigger rival Alcon of its CyPass microstent.
Roland Diggelmann will end his decade-long career at Roche Diagnostics at the end of September. The business's head of EMEA Michael Heuer will take Diggelmann's place while the search is on for his replacement.
Philips has added a new pulse oximetry platform to its patient monitoring portfolio, with the acquisition of Xhale Assurance.